About Aglaris
Aglaris is a company based in Stevenage (United Kingdom) founded in 2012. Aglaris has raised $2.18 million across 6 funding rounds from investors including European Union, EIC Fund and CRB Inverbio. The company has 9 employees as of September 30, 2021. Aglaris offers products and services including Facer 1.0. Aglaris operates in a competitive market with competitors including Limula, PBS Biotech, m2p-labs, RheaVita and Membio, among others.
- Headquarter Stevenage, United Kingdom
- Employees 9 as on 30 Sep, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aglaris Limited
- Date of Incorporation 02 Jul, 2014
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.18 M (USD)
in 6 rounds
-
Latest Funding Round
$856.31 K (USD), Grant
Jan 01, 2021
-
Investors
European Union
& 2 more
-
Employee Count
9
as on Sep 30, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aglaris
Aglaris offers a comprehensive portfolio of products and services, including Facer 1.0.
Bioreactor that improves quality and scalability in cell therapies manufacturing.
People of Aglaris
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aglaris
Aglaris has successfully raised a total of $2.18M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $856.31 thousand completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aglaris
Aglaris has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, EIC Fund and CRB Inverbio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
A private venture capital firm focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Aglaris
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aglaris
Investment portfolio details for Aglaris
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aglaris
Detailed financials for Aglaris
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aglaris Comparisons
Peer comparison for Aglaris
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aglaris
Aglaris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Limula, PBS Biotech, m2p-labs, RheaVita and Membio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Modular solutions for on-demand cell therapy manufacturing are provided.
|
|
| Locked | Locked | Locked |
Developer of single-use bioreactors for the production of vaccines, therapeutic proteins, and cell therapies
|
|
| Locked | Locked | Locked |
Micro-bioreactors are provided for screening and bioprocess development.
|
|
| Locked | Locked | Locked |
Instruments for continuous freeze-drying are developed by RheaVita.
|
|
| Locked | Locked | Locked |
Developer of single-use bioreactors for cell and gene therapies
|
|
| Locked | Locked | Locked |
Bioreactors and systems for cultivated meat production are developed.
|
Detailed competitors of Aglaris
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aglaris
Complete news archive for Aglaris
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aglaris
Aglaris was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Aglaris is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Aglaris is a funded company, having raised a total of $2.18M across 6 funding rounds to date.
As of Sep 30, 2021, the latest employee count at Aglaris is 9.
Aglaris is a biotech company manufacturing fully automated cell culture bioreactor systems for research and industrial applications such as large-scale manufacturing of cells for cell therapies, regenerative medical applications, tissue engineering, and research. The companys flagship product is the Aglaris Facer 1.0 Bioreactor system which is a fully automated cell culture bioreactor that does not require Trypsin for cell dissociation. The reactors design makes it completely automated and minimizes contamination risk by eliminating cell handling at all stages. The companys other product is the Aglaris Micelle Microcarrier, a scaffold material for large scale culture of anchorage-dependent cells in bioreactors. The material has a charged microporous surface, and transparent to allow observation of cells under the microscope with any preparation enabling high yield microcarrier culture of anchorage-dependent cells.
Aglaris's top competitors include PBS Biotech, RheaVita and m2p-labs.
Aglaris offers Facer 1.0.
Aglaris has 3 investors. Key investors include European Union, EIC Fund, and CRB Inverbio.